A multicenter research effort in China conducted clinical trial testing of oral berberine for six months in diabetes-free adults with obesity and metabolic dysfunction-associated steatotic liver disease. Visceral adipose tissue area and liver fat content showed no significant differences between berberine and placebo.
This article was originally published on MedicalXpress.com

